Efficacy and economics of targeted panel versus whole exome sequencing in 878 patients with suspected primary immunodeficiency

BACKGROUND: NGS has become a first-line tool for diagnosis of PID. However, patient access remains limited due to restricted insurance coverage and a lack of guidelines addressing use of targeted panels vs WES. OBJECTIVES: To compare targeted next generation sequencing (NGS) with whole exome sequenc...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Allergy Clin Immunol
Auteurs principaux: Platt, Craig D., Zaman, Fatima, Bainter, Wayne, Stafstrom, Kelsey, Almutairi, Abuarahman, Reigle, Margot, Weeks, Sabrina, Geha, Raif S., Janet, Chou
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7870529/
https://ncbi.nlm.nih.gov/pubmed/32888943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2020.08.022
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires